Tela Bio, Inc. ( (TELA) ) has released its Q1 earnings. Here is a breakdown of the information Tela Bio, Inc. presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TELA Bio, Inc. is a commercial-stage medical technology company specializing in innovative soft-tissue reconstruction solutions, focusing on enhancing clinical outcomes by leveraging the patient’s natural healing process while minimizing the use of permanent synthetic materials.
In its first quarter of 2025, TELA Bio reported a revenue of $18.5 million, marking a 12% increase from the previous year and a 5% sequential growth from the fourth quarter of 2024. The company highlighted increased demand for its OviTex® and OviTex PRS Reinforced Tissue Matrix products, alongside the full U.S. commercial launch of larger-sized OviTex PRS.
Key financial metrics for the quarter included a gross profit of $12.5 million, representing 67.6% of revenue, and operating expenses of $22.9 million, slightly reduced from the previous year. Despite these positive revenue trends, TELA Bio reported a net loss of $11.3 million, compared to a $5.7 million loss in the same period of 2024, attributed in part to the absence of a prior gain from asset sales.
Looking ahead, TELA Bio maintains its full-year revenue guidance of $85.0 million to $88.0 million, anticipating a 23% to 27% growth over 2024. The company remains focused on driving revenue growth and improving operating leverage as it progresses towards profitability.